Recent research advanced understanding of neurotoxicity associated with CAR‑T cell therapies, mapping hemodynamic and cellular events that precede neuroimmune adverse events. The work synthesizes mechanistic signals tied to endothelial activation, cytokine profiles, and blood–brain barrier disruption, and suggests biomarkers and intervention points to mitigate toxicity. Authors recommend targeted monitoring strategies and potential adjunctive treatments to lower neurological risk in CAR‑T recipients. CAR‑T therapy engineers patients’ T cells to recognize tumor antigens; neurotoxicity remains a dose‑limiting safety concern.